Structured evidence table for Coenzyme Q10 Migraine Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coenzyme Q10 Migraine Randomized Trial | In addition to its high prevalence and disability burden, migraine is associated with substantial socioeconomic costs, with estimated direct and indirect expenditures of approximately USD 36 billion annually in the United States []. | 3 | Kozák Márk (2026) | Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics |
| Coenzyme Q10 Migraine Randomized Trial | Clinically, migraine is characterized by recurrent attacks of moderate-to-severe headache lasting 4–72 h, typically unilateral and pulsating, aggravated by routine physical activity, and frequently accompanied by photophobia and phonophobia; in a substantial subset of patients, attacks are associated with reversible focal neurological symptoms called aura. | 3 | Kozák Márk (2026) | Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics |
| Coenzyme Q10 Migraine Randomized Trial | 6 7 8 9 10 11 12 2 13 14 10 15 16 Helicobacter pylori The most common gastrointestinal disorders associated with migraine are irritable bowel syndrome (IBS) (reported in up to 50% of patients with migraine []), inflammatory bowel disease (IBD) [,,], gastroesophageal reflux disease (GERD) [], functional dyspepsia [,], cyclic vomiting syndrome [], peptic ulcers andinfections [,]. | 3 | Kozák Márk (2026) | Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics |
| Coenzyme Q10 Migraine Randomized Trial | 1 2 3 4 2 3 5 Migraine is a prevalent primary headache disorder with significant morbidity and rising prevalence, affecting around 14% of the global population []. | 3 | Kozák Márk (2026) | Migraine and the Gut–Brain Axis—The Role of Microbiome-Targeted Biotics |
| Coenzyme Q10 Migraine Randomized Trial | 1 2 3 4 5 Migraine is a chronic, disabling neurovascular disorder characterized by recurrent episodes of moderate-to-severe headache, typically unilateral and pulsating in quality, and frequently associated with nausea, vomiting, photophobia, and phonophobia. | 3 | Santangelo Domenico (2026) | Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms |
| Coenzyme Q10 Migraine Randomized Trial | These processes result in peripheral and central sensitization of nociceptive pathways, thereby amplifying pain perception and contributing to migraine chronicization []. | 3 | Santangelo Domenico (2026) | Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms |
| Coenzyme Q10 Migraine Randomized Trial | 6 7 6 8 9 10 11 A growing body of evidence indicates that patients with migraine show impaired energy metabolism and reduced metabolic flexibility []. | 3 | Santangelo Domenico (2026) | Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms |
| Coenzyme Q10 Migraine Randomized Trial | In approximately one-third of patients, migraine attacks are preceded or accompanied by transient focal neurological symptoms, known as aura, which most frequently manifests as visual disturbances but may also involve sensory, language, or motor symptoms []. | 3 | Santangelo Domenico (2026) | Dietary Modulation of Migraine: Metabolic, Neuroinflammatory and Microbiota-Mediated Mechanisms |
Source documents